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Abstract
Determining the underlying cause of persistent eosinophilia is important for effective clinical management but remains a
diagnostic challenge in many cases. We identiﬁed STAT5B N642H, an established oncogenic mutation, in 27/1715 (1.6%)
cases referred for investigation of eosinophilia. Of the 27 mutated cases, a working diagnosis of hypereosinophilic syndrome
(HES; n= 7) or a myeloid neoplasm with eosinophilia (n= 20) had been made prior to the detection of STAT5B N642H.
Myeloid panel analysis identiﬁed a median of 2 additional mutated genes (range 0–4) with 4 cases having STAT5B N642H
as a sole abnormality. STAT5B N642H was absent in cultured T cells of 4/4 positive cases. Individuals with SF3B1
mutations (9/27; 33%) or STAT5B N642H as a sole abnormality had a markedly better overall survival compared to cases
with other additional mutations (median 65 months vs. 14 months; hazard ratio= 8.1; P < 0.001). The overall survival of
STAT5B-mutated HES cases was only 30 months, suggesting that these cases should be reclassiﬁed as chronic eosinophilic
leukemia, not otherwise speciﬁed (CEL-NOS). The ﬁnding of STAT5B N642H as a recurrent mutation in myeloid neoplasia
with eosinophilia provides a new diagnostic and prognostic marker as well as a potential target for therapy.
Introduction
Eosinophilia, deﬁned as an elevation of the peripheral blood
(PB) eosinophil count above 0.5 × 109/L, is conventionally
divided into three main categories: primary, secondary
(reactive) and idiopathic. Primary eosinophilia is a clonal
hematologic disorder in which the eosinophils form part of
the neoplastic clone. Secondary, non-clonal eosinophilia
may be driven by a wide range of underlying conditions
including allergic disorders, autoimmunity, infectious dis-
eases, lymphoproliferative disorders, solid tumours, drug
reactions and other conditions. Idiopathic eosinophilia is a
diagnosis of exclusion when no primary or secondary cause
can be identiﬁed [1].
Clonal eosinophilia is seen in the context of a myeloid
neoplasm and particularly the World Health Organisation
(WHO)-deﬁned entities ‘chronic eosinophilic leukemia, not
otherwise speciﬁed’ (CEL-NOS) and ‘myeloid and lym-
phoid neoplasms with rearrangement of PDGFRA,
PDGFRB or FGFR1 or with PCM1-JAK2, ETV6-JAK2 or
BCR-JAK2’ (MLN-eo). Clonal eosinophilia may also be
associated with other WHO subtypes of myeloproliferative
neoplasm (MPN-eo) or myelodysplastic/myeloproliferative
neoplasm (MDS/MPN-eo) [1–3].
Identifying the underlying cause of eosinophilia is
important for patient management but can be challenging
in the absence of an overt myeloid neoplasm or dis-
cernible secondary cause. Primary eosinophilia is strongly
associated with constitutively activated tyrosine kinase
(TK) signalling, and to date more than 70 TK fusion genes
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have been identiﬁed in myeloid neoplasms as a con-
sequence of reciprocal translocations or other genomic
rearrangements [3]. Identiﬁcation of these fusions usually
conﬁrms a speciﬁc diagnosis and is an indication for
targeted therapy. Notably, imatinib induces rapid and
durable complete clinical, hematologic and molecular
remissions in >90% of patients with a PDGFRA or
PDGFRB fusion gene, conferring excellent progression-
free and overall survival (OS) [4, 5]. Fusions involving
JAK2, FGFR1 or FLT3 are associated with a more
aggressive clinical course and may be responsive to other
small molecule inhibitors [6–8]. Some TK-fusion negative
eosinophilia cases test positive for KIT D816V or JAK2
V617F, whereas others have mutations in a range of genes
associated with myeloid neoplasms such as TET2, ASXL1,
EZH2 or SETBP1 [9–11]. It has been suggested that a
rapid and durable response to corticosteroids is uncom-
mon in cases with primary eosinophilia and instead points
towards a diagnosis of secondary eosinophilia, if that is
not already apparent [12].
In this study, we have used genomic approaches to focus
on the identiﬁcation of novel somatic abnormalities in
patients with suspected primary eosinophilia. We have
identiﬁed a recurrent somatically acquired point mutation in
STAT5B leading to an N642H substitution in several cases.
This mutation is known to activate STAT5B but was pre-
viously thought to be restricted to lymphoproliferative
disorders.
Methods
Patients and samples
Our study included samples from individuals referred for
routine diagnostic analysis of persistent unexplained eosi-
nophilia and/or patients diagnosed with MPN or MDS/MPN
with eosinophilia according to standard morphologic,
hematologic and laboratory criteria [2]. Cases that tested
positive for KIT D816V, FIP1L1-PDGFRA or other
recognised TK fusion genes were excluded. The study
design adhered to the tenets of the Declaration of Helsinki
and was approved by the National Research Ethics Service
(UK) Committee South West and the institutional review
board of the Medical Faculty of Mannheim, Heidelberg
University as part of the ‘German Registry on Disorders of
Eosinophils and Mast Cells’. DNA or RNA was extracted
from total PB or bone marrow (BM) leukocytes using
standard procedures. T-cells were selected using CD3
microbeads (Miltenyi Biotech, Cologne, Germany) and
stimulated to divide by co-cultivation with CD2/CD3/CD28
in the presence of interleukin-2 (T-cell activation/expansion
kit; Miltenyi Biotech).
RNAseq analysis
RNAseq data for the initial cohort of 14 cases is available at
ArrayExpress (www.ebi.ac.uk/arrayexpress; accession
number E-MTAB-7492). RNAseq data was analysed for
point mutations using an in-house pipeline. Brieﬂy, raw
RNAseq data in fastq format were aligned to the reference
genome (human_g1k_v37) using STAR aligner and a two-
step process. In the ﬁrst step, splice junctions were detected
by an initial alignment of the fastq ﬁles. In the second step,
ﬁnal alignments were determined using the splice junctions
as a guide [13]. After alignment the bam ﬁles were sorted,
de-duplicated and read groups were added using Picard
(http://broadinstitute.github.io/picard). In preparation for
variant calling, GATK was used to hard-clip intronic
sequences (SplitNCigarReads), reassign mapping qualities
(ReassignOneMappingQuality) and recalibrate base quality
scores (BaseRecalibrator). Variants were called using GATK
HaplotypeCaller and ignoring soft clipped bases, which
minimises false positive and false negative calls. A ﬁnal set
of high-quality variants in variant call format (VCF) was
produced by selecting variants with a phred-scaled con-
ﬁdence threshold of 20 and excluding variants with low
depth corrected quality scores (QD < 2), signiﬁcant strand
bias (FS > 30) or SNP clusters of 3 or more SNPs within 35
base pairs. ANNOVAR [14] was used to annotate variants
with respect to genes, databases of known polymorphisms
(Exome Aggregation Consortium, 1000 genomes, exome
sequencing project, dbSNP), and pathogenicity estimates
(avsift, polyphen, etc.). A shortlist of potentially relevant
variants was created by applying additional ﬁlters, which
excluded non-coding variants, synonymous SNVs and
variants with an alternate allele frequency greater than 1% in
public databases of known variation: 1000 genomes (1000G;
www.ncbi.nlm.nih.gov/variation/tools/1000genomes/),
exome sequencing project (ESP; http://evs.gs.washington.
edu/EVS/) and exome aggregation consortium (ExAC;
http://exac.broadinstitute.org/). Variants passing these ﬁlters
were further highlighted if they were located in a manually
curated list of candidate genes (n= 581 genes), annotated as
pathogenic in Clinvar, overlapped with a somatic mutation
in hematopoietic and lymphoid tissue in COSMIC (https://ca
ncer.sanger.ac.uk/cosmic) or were recurrently mutated.
Ampliﬁcation-refractory mutation system (ARMS)
test for STAT5B N642H
A tetra-primer ARMS assay [15] was designed using http://
primer1.soton.ac.uk/primer1.html with inner primers to
speciﬁcally amplify the normal and mutant STAT5B alleles
and outer primers to produce a positive control STAT5B
band for each reaction. PCR primers were: forward outer
(FO), 5′-CGATCAGGAAACACGTAGATAAGGTAATT-3;
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reverse outer (RO), 5′-AAATGGAGATTTCTATTGGAG
CCATTAT-3; forward wild-type speciﬁc (Fwt), 5′-TCT
CTGGTGGTAAAAGGCATCAGGTT-3; reverse mutant-
speciﬁc (Rmt), 5′-TTATTGATCTAGAGGAAAGAATGT
TTTAGC-3. The FO and RO were used at a ﬁnal con-
centration of 0.5 μM whereas the inner primers Fwt and
Rmt were used at 2.5 μM. Ampliﬁcation reactions were
performed using AmpliTaq Gold DNA polymerase, 25 ng
genomic DNA at an annealing temperature of 60 °C for 35
cycles. Cases showing mutant bands after agarose gel
electrophoresis were conﬁrmed by independent ampliﬁca-
tion followed by Sanger sequencing.
Other mutational analysis
Sanger sequencing was used to screen for other STAT gene
mutations using primers designed to amplify from cDNA:
STAT3 exons 20–22 (5′-GGGCCATCTTGAGCACTAAG-3′
and 5′-CACAGATAAACTTGGTCTTCAGG-3′); STAT5A
exons 16–17 (5′-GGACCTTCTTGTTGCGCTTT-3′ and 5′-
GGCGGTCAGGAAACACATAG-3′) and STAT5B exons
16–17 (5′-AGTGACTCAGAAATTGGCGG-3′ and 5′-GGCC
TGGTCCATGTACGT-3′). ARMS assays were designed for
JAK3 V722I and SOCS1 Q201H. For JAK3 V722I, a standard
tetra primer assay was designed using PCR primers: forward
outer (FO), 5′-CAATAGACCCACCCCAATCTCCCCA-
GAC-3′; reverse outer (RO), 5′-GCAAGGAAGTGGATCC
CTGATCCCACTT-3′; reverse wild-type-speciﬁc (Rwt), 5′-
GCCACGGTCTGGGAAGTGTTTAGTGtCG-3′; forward
mutant-speciﬁc (Fmt), 5′-ATCCAGGGCACTGATGGGCAT
GGTTAT-3′. FO, RO, Rwt and Fmt primers were all used at a
ﬁnal concentration of 0.5 μM in PCR reactions using Ampli-
Taq Gold DNA polymerase, 25 ng genomic DNA and an
annealing temperature of 68 °C for 35 cycles. Design of a tetra
primer assay for SOCS1 Q201H proved to be difﬁcult and
therefore we used a simpliﬁed mutation-speciﬁc assay with
primers forward (F) 5′-CCAGGAGGGGGAGGACCCCCT-
CAAGAGG-3′ and reverse mutant-speciﬁc (Rmt), 5′-CGC
GACTACCTGAGCTCCTTCCCCTTCGAC-3′ at an anneal-
ing temperature of 70 °C for 35 cycles. All ARMS assays were
validated with control samples, and positive/negative controls
were included on each run. The Illumina Trusight Myeloid
Sequencing Panel (Illumina, San Diego, CA) was used to
screen STAT5B-mutated samples for additional somatic muta-
tions. Samples were processed according to the manufacturer’s
protocol, run on an Illumina Miseq and results interpreted using
Alissa Interpret (Agilent, Cheadle, UK) using a variant allele
frequency (vaf) cut off of ≥5%.
Colony growth and sequencing
Mononuclear cells from cryopreserved or fresh primary
cells were grown in methylcellulose with cytokines, without
erythropoietin (Methocult H4035 Optimum), no EPO,
Stemcell Technologies (Vancouver, BC, Canada). DNA
was prepared for sequencing using the PicoPlex whole
genome ampliﬁcation kit (Rubicon Genomics Inc., Ann
Arbor, MI). Colonies were ﬁrst plucked into 80 µl phos-
phate buffered saline, spun down and resuspended in 2.5 µl
of PicoPlex cell extraction buffer followed by DNA
extraction and ampliﬁcation according to the manu-
facturer’s instructions. The DNA was then cleaned up using
the QIAquick PCR puriﬁcation kit (Qiagen, Hilden Ger-
many) prior to ampliﬁcation and Sanger sequencing using
primers designed to target speciﬁc mutations.
Statistical analysis
OS probabilities were estimated using the Kaplan–Meier
method and compared by the log-rank (Mantel–Cox) test
using SPSS v25 (IBM Corporation, Armonk, NY, USA).
OS was deﬁned as the time between diagnosis and the date
of death or last contact.
Results
STAT5B N642H mutation identiﬁed by RNAseq
We previously described RNA-seq analysis to search for
cryptic fusion genes in 14 patients with MPN-eo or idio-
pathic hypereosinophilia with a normal karyotype [6].
Reanalysis of these data for possible point mutations iden-
tiﬁed 10 candidate variants in 6 cases (Table 1). No variants
were seen in 8 cases, including the 2 previously reported to
have DIAPH1-PDGFRB or ZMYM2-FLT3 fusions [6]. Two
of the 6 cases had known myeloid driver mutations: JAK2
V617F in case E166 and SF3B1 K666N in case E11076. Of
the other variants, STAT5B N642H (NM_012448: c.
A1924C) was seen in two cases (E11076 and E11493) and
stood out as this is a known driver mutation in lympho-
proliferative disorders [16]. Furthermore, this mutation was
recently reported in the T-cells and other cell lineages of
two young children with eosinophilia [17].
Identiﬁcation of additional cases with STAT5B
mutations
We used an ARMS assay to rapidly screen additional ret-
rospective cases for STAT5B N642H (Fig. 1a). In an initial
screen, we found that 2/30 cases with suspected MPN-eo
tested positive compared to 0/74 cases with other chronic
myeloid neoplasms. Subsequent screening focused only on
cases referred for investigation of eosinophilia: of 1671
cases screened, 23 further cases tested positive. Overall,
therefore, we found that 27/1715 (1.6%) eosinophilia
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patients harboured STAT5B N642H. For 25/26 cases con-
ﬁrmed by Sanger sequencing, the mutation-speciﬁc peak
was at a similar height or somewhat lower than the wild
type peak, suggesting that the majority of leukocytes were
heterozygous for STAT5B N642H. In one sample (E492)
only the STAT5B mutant peak was seen suggesting the
dominance of a homozygous or hemizygous mutant clone
(Supplementary Figure 1). In 4/4 cases tested, the STAT5B
mutant clone was not detected in cultured T-cells conﬁrm-
ing that it was acquired somatically (Supplementary
Figure 2).
Other STAT mutations
Other somatic STAT5B and STAT3 mutations have been
identiﬁed in lymphoproliferative disorders. To test if these
mutations might also be associated with persistent eosino-
philia, we sequenced known mutation hotspot regions of
STAT3 and STAT5B in 153 cases but no variants were seen
apart from STAT5B N642H. No human mutations have been
reported in STAT5A but due to the high homology with
STAT5B we also sequenced part of this gene, but again no
variants were found (149 cases).
Additional mutations in STAT5B-mutated cases
We screened all 27 STAT5B N642H cases for mutations in
other genes associated with myeloid neoplasms (Fig. 1b).
Overall, mutations were seen in a median of two additional
genes (range 0–4), with 4 cases showing no additional
variants (Group 1). Of note, 9 cases had SF3B1 mutations
(Group 2) of which 4 were detected as sole additional
abnormalities, 3 were seen in combination with single
mutations in TET2 or DNMT3A and 2 had additional
mutations in genes encoding signalling or splicing compo-
nents. Fourteen cases did not have SF3B1 mutations but
instead had a diverse range of epigenetic, signalling, tran-
scription factor and other splicing mutations with no clear
patterns emerging in terms of co-mutated genes (Group 3).
All additional mutations are detailed in Supplementary
Table 1.
Clinical features associated with STAT5B N642H and
other mutations
The clinical features for all cases are summarised in Table 2.
There was a preponderance of males (19 males, 8 females)
and the median age was 70 (range 7–89; n= 27) with a
median eosinophil count at the presentation of 6 × 109/L
(range 0.5–27; n= 26). In most cases eosinophilia was
apparent at diagnosis but in 3 cases this was acquired during
the course of myelodysplastic syndrome (MDS; cases
E2594 and E11837) or MPN (case E13661). Basophilia was
noted in several cases. A working diagnosis of idiopathic
hypereosinophilic syndrome (HES) had been made in 7
cases prior to the ﬁnding of STAT5B N642H and CEL-NOS
in 2 cases, supported by the ﬁnding of an additional chro-
mosome 8 by cytogenetic analysis in both cases. The
Kaplan–Meier estimate for OS of STAT5B-mutated HES
cases was only 30 months, which is very short compared to
published series [11], and suggests that these cases should
be reclassiﬁed as CEL-NOS [10]. The remaining 18 cases
had been diagnosed with another myeloid neoplasm, most
commonly a subtype of MDS/MPN (n= 11). The PB and
BM from a representative case with CEL-NOS and STAT5B
N642H as a sole abnormality are shown in Fig. 2.
There was no obvious correlation between the clinical
diagnosis and the molecular classiﬁcation described above.
For example, the 7 cases initially diagnosed with HES were
split between molecular group 1 (n= 1), group 2 (n= 2)
and group 3 (n= 4) and the 9 cases with SF3B1 mutations
had been diagnosed with 7 different entities, including HES
(n= 2) and 6 WHO-deﬁned subtypes of myeloid neo-
plasms. There was, however, a clear correlation between
molecular features and outcome. Focusing on patients with
eosinophilia at diagnosis, the OS for cases in group 3 was
markedly inferior to cases in groups 1 and 2 [median
14 months vs. 65 months; hazard ratio (HR)= 8.1 (95% CI:
1.9–23); P < 0.0004, Fig. 3a]. By contrast age, gender and
white cell count were not signiﬁcantly associated with OS
in this relatively small group, whereas eosinophil count
approached signiﬁcance (≤6 × 109/L, 49 months vs. >6 ×
109/L, 17 months; P= 0.06). No signiﬁcant effect of
mutation number was seen when all mutations were con-
sidered but, interestingly, when genes strongly associated
with age-related clonal hematopoiesis (i.e. DNMT3A and
TET2) were excluded from the analysis, the OS for cases
with mutations in 2 or more additional genes was sig-
niﬁcantly worse than that of cases with 0 or 1 additional
mutations [median 18 months vs. 50 months; HR= 6.5
(95% CI: 2.1–30) P= 0.001, Fig. 3b].
Table 1 Candidate variants identiﬁed by RNAseq analysis
Case Gene Refseq cDNA Protein vaf
E166 JAK2 NM_004972 c.G1849T p.V617F 1.00
E166 SOCS1 NM_003745 c.G630C p.Q210H 0.48
E11072 RPS19 NM_001022 c.C164T p.T55M 0.48
E11072 SOCS1 NM_003745 c.G630C p.Q210H 0.86
E11075 PRF1 NM_001083116 c.A755G p.N252S 0.39
E11076 SF3B1 NM_012433 c.G1998T p.K666N 0.32
E11076 PRF1 NM_001083116 c.A755G p.N252S 0.67
E11076 STAT5B NM_012448 c.A1924C p.N642H 0.43
E11493 STAT5B NM_012448 c.A1924C p.N642H 0.47
E11500 JAK3 NM_000215 c.G2164A p.V722I 0.56
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As for therapy, 5 patients were treated with imatinib for
at least 2 months but none responded. One patient with KIT
D816V-positive systemic mastocytosis with associated
hematologic neoplasm (SM-AHN) responded to mid-
ostaurin but the response was lost after 9 months. Some
patients showed clinical improvement and reduction in
eosinophil counts with corticosteroids but in most cases this
was partial and/or transient.
Clonal hierarchy
To understand if the acquisition of STAT5B N642H is an
early or late event in the development of myeloid neoplasia,
we genotyped myeloid colonies grown from 4 cases with
multiple mutations. For case E10926, 6 mutations in 5
genes had been identiﬁed by bulk analysis. By colony
analysis, we found a major clone with 5 mutations that
included STAT5B N642H and KRAS V14I but not KIT
D816V, and a minor clone that included KIT D816V but not
STAT5B N642H or KRAS V14I. All colonies tested positive
for SF3B1 and two independent TET2 mutations and thus
branching evolution can be inferred with STAT5B N642H
acquired in a later subclone. For 2 of the other cases, linear
evolution was apparent with STAT5B and ASXL1 mutations
acquired as late events. The fourth case was uninformative
with all colonies positive for the 3 mutations detected on
bulk analysis (Fig. 4a). For two cases with increasing
eosinophil counts, the STAT5B N642H vaf, as estimated by
Sanger sequencing, increased over time (Fig. 4b).
Assessment of other variants identiﬁed by RNAseq
Other recurrent mutations identiﬁed by RNAseq were also
considered. Both PRF1 N252S and SOCS1 Q210H were
identiﬁed in two individuals (Table 1). PRF1 encodes per-
forin 1, a gene associated with familial hemophagocytic
lymphohistiocytosis. However, the N252S variant has been
shown to be a non-functional rare single nucleotide poly-
morphism (SNP) and was therefore not considered further
[18]. SOCS1 encodes suppressor of cytokine signalling 1,
which takes part in a negative feedback loop to attenuate
cytokine signalling and therefore has obvious potential
relevance to myeloid neoplasia. The status of the Q210H
variant is unclear: it is seen at a frequency of 0.2–0.6% in
the 1000G, ESP and ExAC control datasets, as are some
known somatic driver mutations such as JAK2 V617F. For
one case, we tested buccal cells and found the variant was
constitutional (data not shown). To test the possibility that
Q210H might be more widespread in myeloid neoplasia, we
tested cases referred for investigation of eosinophilia (n=
100bp
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Fig. 1 a ARMS assay for
STAT5B N642H. Heterozygotes
have 3 bands—control band
(243 bp), wild type (wt) speciﬁc
band (166 bp) and mutant allele
speciﬁc band (124 bp). Using
serial dilutions of DNA from a
mutated case we estimated that
the assay can detect STAT5B
N642H at a variant allele
frequency of 10%. b Summary
of mutations for all 27 STAT5B
N642H mutated cases as
determined by ARMS PCR,
Sanger sequencing and myeloid
panel analysis. Group 1 are
cases with no additional mutated
genes, group 2 have additional
mutated genes that include
SF3B1 and group 3 have
additional mutated genes that do
not include SF3B1. ARCH=
genes strongly associated with
age-related clonal
hematopoiesis. Full details of
additional mutations are given in
Supplementary Table 1
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151), mastocytosis (n= 75), MDS/MPN (n= 54) and
healthy controls (n= 88). Just 3 (1%) cases tested positive
(one with mastocytosis, 2 with MDS/MPN) and none of the
controls (P= 0.99; Fisher’s exact test) suggesting that this
variant is an irrelevant, rare polymorphism that happened to
be present in 2 of the cases analysed by RNAseq. JAK3
V722I was seen in a single case and has been reported
previously as an activating mutation [19] but is also present
at 0.4–1% in control datasets and its pathogenicity has been
disputed. We found that 4/307 cases with suspected mye-
loid neoplasia tested positive for JAK3 V722I (one of which
also had the mutation in cultured T-cells) as well as 3/88
normal controls (P= 0.19), again suggesting it is an irre-
levant polymorphism. Similarly, RPS19 T55M is also
believed to be a polymorphism [20].
Discussion
STAT5 is a key component of cytokine-induced signal
transduction cascades, and a critical downstream med-
iator of transformation by oncogenic TKs such as BCR-
Table 2 Clinical summary of
STAT5B N642H mutant cases
Case Sex Age (y) Status (m) wcc plt Hb eos Initial diagnosis MG
E143 M 69 D (107) 16 280 100 1.5 aCML 2
E228 M 65 n/a n/a n/a n/a n/a HES 2
E492 F 7 D (13) 30 343 147 11 Myeloid sarcoma 3
E1237 M 89 D (12) 15 488 148 6 MPN-U 3
E2323 M 70 D (12) 61 107 101 10 CMML 3
E2335 M 63 D (9) 28 113 158 0.7 MDS/MPN 3
E2594 M 58 D (14) 14 128 81 4 MDS-SLD; eosinophilia at 3 years 2
E2810 M 81 D (7) 18 409 94 10 MPN-U 2
E2935 F 10 D (48) 47 157 110 27 HES 1
E3065 F 82 D (28) 25 150 100 2 CMML+MM 1
E3321 M 86 D (45) 21 n/a 152 6 HES 2
E4349 M 61 D (12) 15 16 132 5 CMML 3
E5735 M 68 D (31) 12 106 111 5 HES 3
E10926 M 70 D (16) 142 111 73 1.4 SM-AHN 2
E11076 M 72 A (68) 21 556 149 6 MDS/MPN-U 2
E11493 M 76 D (23) 42 275 92 19 MDS/MPN-U 3
E11825 F 61 A (61) 9 438 108 1.2 MDS/MPN-RS-T 2a
E11837 M 72 D (14) 11 120 156 7 MDS-MLD; eosinophilia at 3 years 1
E12398 M 77 D (15) 24 34 140 7 HES 3a
E12433 F 51 A (35) 19 151 90 3 MDS/MPN-U 2
E12601 F 64 D (14) 28 267 116 10 HES 3
E12614 F 15 A (48) 28 655 133 4 CEL-NOS 1a
E12885 F 75 D (23) 24 238 110 3 MDS/MPN 3a
E13191 M 83 A (9) 29 401 148 13 HES 3
E13206 M 85 D (4) 39 229 142 20 CEL-NOS 3
E13493 M 70 D (9) 17 195 65 6 MDS/MPN-U 3
E13661 M 42 A (60) 12 267 125 0.5 PV; eosinophilia at 25 years 3
Sex: male (M) or female (F); Age in years (y) at presentation; Status: dead (D) or alive (A) at speciﬁed
number of months (m) after presentation or ﬁrst detection of eosinophilia (E2594, E11837, E13661); white
cell count (wcc), platelets (plt) and eosinophils (eos) ×109/L at diagnosis or ﬁrst detection of eosinophilia;
haemoglobin (Hb) in g/L; diagnosis: atypical chronic myeloid leukemia (aCML), hypereosinophilic
syndrome (HES), myeloproliferative neoplasm, unclassiﬁable (MPN-U); myelodysplastic/myeloproliferative
neoplasm (MDS/MPN), myelodysplastic syndrome with single lineage dysplasia (MDS-SLD), chronic
myelomonocytic leukemia (CMML), multiple myeloma (MM), systemic mastocytosis with associated
hematological neoplasm (SM-AHN), MDS/MPN, unclassiﬁable (MDS/MPN-U), MDS/MPN with ring
sideroblasts and thrombocytosis (MDS/MPN-RS-T), MDS with multilineage dysplasia (MDS-MLD),
chronic eosinophilic leukemia, not otherwise speciﬁed (CEL-NOS), polycythemia vera (PV); molecular
group (MG): 1= no additional mutations; 2= SF3B1 mutated; 3= additional mutations but SF3B1
unmutated; not available (n/a)
aIndicates the 4 cases for whom STAT5B N642H was absent in cultured T-cells
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ABL1, JAK2 V617F, FLT3-ITD and ZNF198-FGFR1
[21–25]. STAT5 is encoded by two different genes,
STAT5A and STAT5B, located closely together at chro-
mosome 17q11.2 that encode proteins with >90% amino
acid identity and largely redundant functions. Never-
theless, targeted disruption of STAT5A and STAT5B
gives rise to distinct phenotypes in mice and only
STAT5B has been reported to be a target of mutations in
cancer [26].
STAT5A N642H was initially identiﬁed as a con-
stitutively activating mutation in a random ex vivo muta-
genesis screen [27]. The corresponding mutation in STAT5B
was subsequently identiﬁed as a somatically acquired driver
mutation in 1–37% of patients with various lymphoid
neoplasms including large granular lymphocytic leukemia
[16], paediatric T-cell acute lymphoblastic leukemia [28],
T-cell prolymphocytic leukemia [29], γδ-T-cell lymphoma
[30] and two cases of lymphocyte-driven early onset non-
clonal eosinophilia with urticaria, dermatitis and other fea-
tures [17]. The most frequent mutation seen in these T-cell
disorders is STAT5B N642H, but other mutations are also
seen, speciﬁcally STAT5B Y665F and STAT3 Y640F,
N647I and D661V/Y [31]. Isolated reports have identiﬁed
single cases of myeloid neoplasms, speciﬁcally chronic
neutrophilic leukemia [32] and MLN-eo [33], that tested
positive for STAT5B N642H as well as 2 cases that devel-
oped clonal hematopoiesis following aplastic anaemia [34].
Our ﬁndings are the ﬁrst to identify STAT5B N642H as a
recurrent mutation in myeloid neoplasms with eosinophilia.
We demonstrated the absence of STAT5B N642H in
cultured T-cells from 4 cases, one of whom (case E12614)
was in molecular group 1, i.e. had no additional mutations.
All 4 group 1 cases, and indeed most cases in this study, had
STAT5B vafs which suggested the great majority of leuko-
cytes were heterozygously mutated (Supplementary Fig-
ure 1). Although we cannot exclude the possibility that
some T-cell subsets might be part of the mutant clone, our
data strongly suggest that STAT5B N642H drives primary
eosinophilia irrespective of the presence or absence of
additional mutations.
Cytokine stimulation results in phosphorylation of
STAT5B by receptor or non-receptor TKs. Dimerization of
tyrosine phosphorylated (pY) STAT5B is mediated by
trans-SH2 domain/phosphotyrosine binding, and the dimers
then translocate to the nucleus and activate transcription of
target genes [26]. N642 is located within the SH2 domain of
STAT5B, close to the phosphotyrosine-binding loop.
Rather than being constitutively active, the N642H mutant
shows prolonged pY-STAT5 levels upon cytokine stimu-
lation due to greatly enhanced stability of N642H homo-
dimers [30]. Transgenic expression of STAT5B N642H
under the control of the Vav1 promoter (which is believed to
be active in all hematopoietic cell types, including stem
cells) resulted in transplantable CD8+ T-cell neoplasia.
Fig. 2 Peripheral blood ﬁlm (a), bone marrow smear (b) and bone
marrow trephine biopsy section at ×20 (c) and ×100 (d). The blood
ﬁlm showed 40% neutrophils, 28% eosinophils, 4% basophils, 12%
lymphocytes and 7% monocytes. The eosinophils were morphologi-
cally close to normal with only a very minor degree of vacuolation and
hypogranularity but there was an increase in non-lobated forms. Bone
marrow cellularity and megakaryocyte numbers were increased. The
increased cellularity was due to an increase in all three granulocyte
lineages (neutrophils, basophils and eosinophils). The trephine biopsy
sections show hypercellularity, disorganisation and an increase in cells
of neutrophil and eosinophil lineages. Reticulin was not increased
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Although eosinophilia was not noted, there was a mild
expansion of mature and immature myeloid lineage cells
[35]. The apparent absence of myeloid neoplasia with
eosinophilia in this mouse model may be the result of a
number of factors, including the precise expression of
STAT5B, the effect of other somatic mutations, the cell type
in which STAT5B N642H arises and the rapid onset of T-
cell neoplasia.
We observed a striking inﬂuence of additional muta-
tions on patients with STAT5B N642H that mirrors
established associations in related myeloid disorders,
particularly the relatively good prognostic inﬂuence of
SF3B1 mutations and the adverse inﬂuence of multiple
mutations, both of which have been described in MDS
[36, 37]. In addition, only one case with an SF3B1
mutation tested positive for one or more mutations in
SRSF2, ASXL1 and RUNX1 (S/A/R), known to be an
adverse prognostic factor in advanced SM [38], whereas
10/14 cases in group 3 were S/A/R positive (P= 0.009;
Fisher’s exact test).
The combination of JAK2 V617F and SF3B1 mutations
is associated with MDS/MPN with ring sideroblasts and
thrombocytosis [39]. In our series, the working diagnosis of
patients with STAT5B N642H and SF3B1 mutations ranged
from HES to MDS/MPN (Table 2). Stored material from
most cases was not available for central morphological
review but we envisage that prospective analysis of new
cases will help to deﬁne more accurately the features
P=0.001
A
Time (months)
O
ve
ra
ll 
su
rv
iv
al
120100806040200
1.0
0.8
0.6
0.4
0.2
0
120100806040200
1.0
0.8
0.6
0.4
0.2
0
O
ve
ra
ll 
su
rv
iv
al
B
0-1 addional genes (n=14)
≥2 addional genes (n=9)
P<0.001
Group 1 (n=3)
Group 2 (n=7)
Group 3 (n=13)
Fig. 3 Kaplan–Meier plots showing overall survival (OS) estimates for
the STAT5B N642H mutated cases who had eosinophilia at diagnosis
and had follow up data available (n= 23). a Comparison of the 3
molecular groups shows that cases in group 3 (those with additional
mutated genes that do not include SF3B1) have an inferior OS com-
pared to all other cases (median 14 months vs. 65 months; P < 0.0004).
b OS for cases with mutations in 2 or more additional genes (excluding
DNMT3A and TET2) was signiﬁcantly worse than that for cases with 0
or 1 additional mutations (median 18 months vs. 50 months; P=
0.001). Of the 9 cases with mutations in ≥2 additional genes, 8 were in
group 3
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Fig. 4 a Clonal hierarchy for 4 patients. The numbers indicate the
number of colonies with that genotype, e.g. for case E11825, 5
colonies were mutant for TET2 and SF3B1 but not STAT5B and 9
colonies were mutant for all 3 genes. Light grey indicates an inferred
ancestral clone. b Sequential analysis of two cases with increasing
eosinophil counts (values indicated are ×109/L). Case E11825 had an
elevated eosinophil count at diagnosis, with eosinophilia increasing
over time co-incident with an increase in STAT5B N642H vaf. Case
E13661 was diagnosed initially with PV in 1988 and STAT5B N642H
was not detected in a sample taken 6 years later. Slightly elevated
eosinophil counts were ﬁrst noted in 2014, and a sample from this time
was positive for STAT5B N642H. The mutant vaf and eosinophil
counts increased over the next 4 years
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associated with STAT5B N642H in the presence or absence
of SF3B1 mutations.
Previous studies have shown that STAT5A is required
for eosinophil differentiation of cord blood-derived CD34+
cells [40]. Our ﬁndings, however, suggest that STAT5B
N642H may be a driver of eosinophilia. First, in most of our
cases eosinophilia was apparent at diagnosis and the level of
STAT5B N642H as assessed by Sanger sequencing indi-
cated that the mutation was present in the majority of cells.
In 4 of these cases STAT5B N642H was detected as a sole
abnormality, although we cannot exclude the possibility of
mutations in genes not covered by the myeloid panel.
Second, analysis of 2 cases with increasing eosinophil
counts showed an increase in the STAT5B N642H vaf.
Three additional cases acquired eosinophilia during the
course of their disease but unfortunately samples were not
available for analysis from the pre-eosinophilia phase.
The ﬁnding that STAT5B N642H shows prolonged acti-
vation following cytokine signalling suggests that targeting
upstream TKs may ameliorate the activity of mutant
STAT5B. Indeed, the T-cell neoplasms induced by transgenic
STAT5B N642H was markedly suppressed by JAK1/2 inhi-
bition [35]. Furthermore, a small molecule inhibitor of
STAT5B dimerization has been shown to inhibit the growth
of FLT3-ITD positive AML cells [41]. Further studies will be
required to determine if myeloid disorders associated with
STAT5B N642H are targetable with small molecule inhibitors.
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